Evidence-based Preclinical Medicine
© John Wiley and Sons
Articles are published under the terms of the Creative Commons Attribution License.
Edited By: David Howells, PhD and Malcolm Macleod, PhD FRCP
Online ISSN: 2054-703X
Recently Published Issues
Open for Submissions
Evidence-based Preclinical Medicine (EBPM) publishes open access, high quality systematic reviews, meta-analyses and protocols summarizing data from animal studies on a subject relevant to human health. EBPM is an essential source of knowledge for all those involved in basic biomedical research and its potential application to human health, including the development of new drugs and therapeutic approaches and the assessment of compounds potentially hazardous to human health.
GOOD NEWS!Evidence-based Preclinical Medicine is now indexed by the Directory of Open Access Journals (DOAJ)
Evidence-based Preclinical Medicine is more than just a journal:
• The EBPM helpdesk guides practitioners through the processes of systematic review and help authors prepare the study dataset for publication.
• Protocols of systematic reviews enable readers to distinguish between a priori hypothesis and post-hoc observations.
• All datasets are held in a public repository. EBPM provides tools to access data, ensuring that information collected in the context of systematic reviews will be available to all. The costs of deposition are included in the publication costs and deposited by the helpdesk on request.
More reasons to publish with Evidence-based Preclinical Medicine (EBPM):
• High standard, rigorous peer review
• Immediate open access
• Fully compliant with all open access mandates
• Authors retain copyright. Articles published under the Creative Commons Attribution (CC BY) License
Meet the Editors
David Howells is co-division head of the stroke division at The Florey Institute of Neuroscience and Mental Health. He began his career studying folate and biopterin metabolism and the consequent immunological and neurochemical changes in children with rare genetic defects at Great Ormond Street Hospital for Sick Children. He then went on to demonstrate links between host neurochemical and inflammatory responses to injury, including the role of BDNF in Parkinson’s disease and the discovery of a new population of dopaminergic neurons in these patients. His other research interest is in stroke where he has collaborated in making systematic review and meta-analysis valued tools in the evaluation of the basic science literature, and helped generate widely accepted standards for the conduct of translational stroke research, and new hypotheses for testing in the laboratory and the clinic.
Malcolm Macleod is Professor in Neurology and Translational Neuroscience at the Centre for Clinical Brain Sciences, University of Edinburgh, and Head of Neurological Diseases, Stroke and Acquired Brain Injury at NHS Forth Valley. He started his career investigating the neuroprotective actions of FK506, before defining a neuroprotective role for increased expression of the mineralocorticoid receptor. After becoming involved with stroke clinical trials, he helped found CAMARADES (Collaborative Approach to Meta-analysis and Review of Animal Data from Experimental Studies) which has found application in a range of models. He has served on the UK Home Office Animals in Science Committee since 2013 and is chair of the 3Rs sub-committee, and is also a member of the UK Commission on Human Medicines.